# **Naturhouse Health**





**EQUITY - SPAIN** 

Sector: Personal Products

Report date: 2 Mar 2022 Distribution time: 13:30 12m Results 2021 Closing price: EUR 1.88 (1 Mar 2022)

Luis Esteban Arribas – luis.esteban@lighthouse-ieaf.com

12m Results 2021

Opinion (1): In line

Impact (1): We will maintain our estimates

+34 915 904 226

#### **Business description**

Naturhouse Health (NTH) is a small family group with headquarters in Madrid (Spain), specialising (c. 30 years) in nutrition and the re-education of eating habits (dietetics). With an international presence (c. 80% of revenue; France, Italy and Poland being its core markets). It is managed and controlled by the founding family (77.1% of capital).

### Market Data

| Market Cap (Mn EUR and USD)    | 112.8      | 125.7    |
|--------------------------------|------------|----------|
| EV (Mn EUR and USD) (2)        | 90.6       | 101.0    |
| Shares Outstanding (Mn)        | 60.0       |          |
| -12m (Max/Med/Mín EUR)         | 2.06 / 1.7 | 9 / 1.55 |
| Daily Avg volume (-12m Mn EUR) | 0.06       |          |
| Rotation <sup>(3)</sup>        | 12.4       |          |
| Factset / Bloomberg            | NTH-ES /   | NTH SM   |
| Close fiscal year              | 31-Dec     |          |

### **Shareholders Structure (%)**

| Mr. F. Revuelta & Family | 76.7 |
|--------------------------|------|
| Free Float               | 23.3 |

### Relative performance (Base 100)



## Stock performance (%)

|                         | -1m  | -3m  | -12m  | -5Y   |  |
|-------------------------|------|------|-------|-------|--|
| Absolute                | 0.5  | -1.3 | 1.9   | -58.6 |  |
| vs Ibex 35              | 7.1  | 1.9  | 4.3   | -50.7 |  |
| vs Ibex Small Cap Index | 1.0  | -4.0 | 7.0   | -72.2 |  |
| vs Eurostoxx 50         | 12.8 | 9.5  | 0.3   | -62.8 |  |
| vs Sector benchmark(4)  | 2.6  | -0.9 | -13.3 | -67.6 |  |

- (1) The opinion regarding the results is on reported EBITDA with respect to our estimate for the year (12m). The impact reflects whether, due to the results, we envisage a significant revision (>5% 10%, depending on the sector) of our EBITDA estimate (for any of the estimated years).
- (2) Please refer to Appendix 2.
- (3) Rotation is the % of the capitalisation traded 12m.
- (4) vs Stoxx Europe 600 Food & Beverage.

(\*) Unless otherwise indicated, all the information contained in this report is based on: The Company, Factset and Lighthouse.

# 2021: Slow recovery of revenue. EBITDA, in line. An idea waiting to be discovered

**REVENUE STILL BELOW 2019 (EUR 57.9MN, +3.0% VS 2020)** ... Despite the end of the Covid-19 restrictions, NTH closed 2021 with similar figures to those seen in 2020. There were very different rates of recovery by country: France, NTH's core market, reached EUR 20.2Mn (-2.4% vs 2020; 35% of revenue); Italy was the best performing country in the year with EUR 16.8Mn (+18.1% vs 2020; 29% of revenue); Spain (EUR 11.9Mn, +6.1% vs 2020; 21% of revenue) and the other countries were almost flat vs 2020.

... ALTHOUGH THE ONLINE CHANNEL CONTINUES TO GET STRONGER. NTH has committed to the online channel (since 2020). This is still a small business line accounting for 3.7% of total revenue in 2021 (+113% y/y). Growth in on-line sales remains a strategic long-term target for NTH.

### STRONG RECOVERY OF THE REC. EBITDA/SALES MARGIN (35.4% 2021 VS 30.9% IN

**2020)** ... NTH's strategy of restructuring its own centres and closing the less profitable ones (1,686 centres in 2021 vs 2,188 in 2019; taking into account own centres and franchises) represented a turning point in 2021. Rec. EBITDA was EUR 20.5Mn in 2021 (vs EUR 17.4Mn in 2020; +18.1%). This result was partly justified by the fall in personnel expenses (-13.0% vs 2020), that allowed the company to maintain EBITDA fully in line with our estimates despite lower revenue.

...THAT CONSOLIDATED THE CAPACITY FOR CASH GENERATION. NTH's business model is underpinned by a cost-light structure that, in 2021, was reduced even further obtaining Rec. FCF of EUR 14.1Mn. The restriction on dividend payments in 2020, due to Covid-19 legislation (government furlonugh schemes) meant net cash (ex IFRS 16) in 2021 was EUR 25.1Mn. NTH proposes payment of a EUR 12Mn dividend (EUR 0.2/share) to be paid against 2021 earnings, that represents a pay-out of c. 90% (yield of 10.6%).

IN CONCLUSION, AND NOW WHAT?... Despite smaller than estimated revenue, profitability levels in 2021 have enabled significant growth. We maintain our estimates in the light of results (EBITDA) in line that should allow NTH to achieve sales of EUR 68 Mn and Rec. EBITDA of EUR 22Mn in 2022e. NTH is currently trading at c. 4.4x EV/EBITDA 2021, a FCF yield >12.5% and P/E of 8.4x.

**2018-2021:** MARGIN VS REVENUE The -3y snapshot is revealing. Excellent management of the structure to overcome the difficulty in growing revenue (competition, Covid-19). The c.+20% in EBITDA in 2021 suggests an inflexion point and the opportunity to lever the current efficient structure on a larger volume of revenue. The "wheel to follow" is the Italian market. If we extrapolate the recovery seen in this market (2021, c.+20%) to the rest, we would be talking about sales of c. EUR 70 Mn, to which in theory we would have to apply margins (2021) of c.35%, and that "mathematically" implies very significant upside. This is NTH's equity story (beyond the already excellent 2021 FCF yield).

| EUR Mn                | 2018  | 2021  | TACC -3y |
|-----------------------|-------|-------|----------|
| <b>Total Revenues</b> | 88.7  | 57.9  | -13.2%   |
| Recurrent EBITDA      | 23.2  | 20.5  | -4.0%    |
| Rec. EBITDA/Revenues  | 26.2% | 35.4% | 10.6%    |







# Appendix 1. Results table

| EUR Mn                | 12m21<br>Real | 12m20  | 12m21 Real<br>vs 12m20 | 2021e  | 12m2021 Real<br>vs 2021e |
|-----------------------|---------------|--------|------------------------|--------|--------------------------|
| Total Revenues        | 57.9          | 56.2   | 3.0%                   | 64.2   | -9.8%                    |
| France                | 20.2          | 20.7   | -2.4%                  |        |                          |
| Spain                 | 11.9          | 11.2   | 6.3%                   |        |                          |
| Italy                 | 16.8          | 14.2   | 18.1%                  |        |                          |
| Poland                | 6.9           | 7.2    | -3.3%                  |        |                          |
| RoW                   | 1.8           | 1.8    | -1.8%                  |        |                          |
| Other income          | 0.3           | 1.2    | -70.3%                 |        |                          |
| Recurrent EBITDA      | 20.5          | 17.4   | 18.1%                  | 21.2   | -3.1%                    |
| Rec. EBITDA/Revenues  | 35.4%         | 30.9%  | 4.5 p.p.               | 33.0%  | 2.4 p.p.                 |
| EBITDA                | 20.3          | 17.4   | 16.2%                  | 21.2   | -4.4%                    |
| EBITDA/Revenues       | 35.0%         | 31.0%  | 4.0 p.p.               | 33.0%  | 2.0 p.p.                 |
| EBIT                  | 17.8          | 14.2   | 25.6%                  | 18.6   | -4.1%                    |
| PBT                   | 18.2          | 13.5   | 35.0%                  | 18.9   | -3.5%                    |
| NP                    | 13.4          | 9.4    | 42.5%                  | 12.9   | 3.3%                     |
| Ordinary NP           | 13.6          | 9.4    | 44.1%                  | 13.2   | 2.6%                     |
| Nr. Of Centers        | 1,686         | 1,788  | -102                   | 1,788  | -5.7%                    |
| Online Sales (%)      | 3.9%          | 1.8%   | 2.1 p.p.               | 2.3%   | 1.6 p.p.                 |
| Rec. FCF              | 14.1          | 8.8    | 59.5%                  | 12.4   | 14.1%                    |
| Rec. FCF Yield        | 12.5%         | 7.8%   | 4.7 p.p.               | 11.0%  | 1.5 p.p.                 |
| Net Cash <sup>1</sup> | -25.1         | -17.0  | -47.3%                 | -25.8  | 2.7%                     |
| Net Cash / EBITDA     | -1.2 x        | -1.0 x | -0.2 x                 | -1.2 x | 0.0 x                    |

Net Cash adjusted in order to exclude the IFRS 16 impact (EUR 2.2Mn and EUR 3.6Mn en 2021 and 2020, respectively).

# Appendix 2. EV breakdown at the date of this report

|                                      | EUR Mn | Source           |
|--------------------------------------|--------|------------------|
| Market Cap                           | 112.8  |                  |
| + Minority Interests                 | 0.1    | 12m Results 2021 |
| + Provisions & Other L/T Liabilities | 1.5    | 12m Results 2021 |
| + Net financial debt                 | (25.1) | 12m Results 2021 |
| - Financial Investments              | (1.4)  | 12m Results 2021 |
| +/- Others                           |        |                  |
| Enterprise Value (EV)                | 90.6   |                  |

# **Naturhouse Health**

(NTH-ES / NTH SM) Report date: 2 Mar 2022

# IMPORTANT LEGAL INFORMATION REGARDING THIS REPORT

### LIGHTHOUSE

Lighthouse is a project of IEAF Servicios de Análisis S.L.U. Lighthouse is a research project funded by Bolsas y Mercados Españoles S.A. Lighthouse aims to improve the research coverage of the "orphan stocks" of the Spanish market: those which lack real and continuous research coverage. Lighthouse reports will not include valuation and target price. Lighthouse does not seek to provide investment advice to any natural or legal person. For this reason, Lighthouse will not provide a valuation, target price or investment recommendation for any of the securities analysed.

IEAF Servicios de Análisis S.L.U. is a Spanish company whose corporate purpose is:

- 1°) To provide information and financial analysis regarding securities issued by any class of legal person traded or not on official secondary markets, and especially (but not exclusively) those securities which are not the object of the recurrent provision of information and analysis by financial analysts who participate in the markets.
- 2°) To publicise and update the aforementioned financial reports and analysis, in addition to the monitoring and following of the securities on which the information and analysis is provided.
- 3°) To prepare studies and projects aimed at proposing and implementing measures to improve the information and financial analysis of securities traded on official secondary markets.
- IEAF Servicios de Análisis S.L.U. is a company whose sole shareholder is the Instituto Español de Analistas Financieros (IEAF), a professional, not for profit association.

#### **DISCLAIMER**

The Instituto Español de Analistas Financieros (IEAF) hereby certifies that the analyst of IEAF Servicios de Análisis S.L.U. whose name figures as the author of this report, expresses views that reflect their personal and independent opinion of the company analysed without these implying, either directly or indirectly, a personalised recommendation of the company analysed for purposes of providing investment advice. This report is based on the preparation of detailed financial projections from information available to the public and following traditional fundamental research methodology (i.e. it is not a technical or quantitative analysis report). For the analysis methodology used in the preparation of this report, please contact the analyst directly; contact details are included on the front page of this report.

The report includes basic information regarding the main parameters to be used by an investor when making their own valuation (whether by discounted cash flows or multiples). These parameters are the personal opinion or estimate of the analyst. The person receiving this report should use their own judgement when using these parameters and should consider them as another element in their decision-making process in respect of investment. These parameters do not represent a personalised investment recommendation.

#### Rules governing confidentiality and conflicts of interest

None of the following rules governing confidentiality and conflicts of interest (12) is applicable to this report:

- 1. This report is non-independent research as it has been commissioned by the company analysed (issuer).
- 2. In the last 12 months, the Instituto Español de Analistas Financieros or its subsidiary, IEAF Servicios de Análisis S.L.U., has had Investment Banking mandates or has managed or comanaged a public offering of the securities of the issuer, or has received compensation from said issuer for Investment Banking services, that exclude brokerage services for prepaid fees
- 3. In the next 6 months, the Instituto Español de Analistas Financieros or its subsidiary, IEAF Servicios de Análisis S.L.U., expects to receive or intends to obtain compensation for Investment Banking services provided to this company that exclude brokerage services for prepaid fees.
- 4. The Investment Analyst or a member of the Research Department or a member of their household has a long position in the shares or derivatives of the corresponding issuer.
- 5. The Investment Analyst or a member of the Research Department or a member of their household has a short position in the shares or derivatives of the corresponding issuer.
- 6. At the date of publication, the Instituto Español de Analistas Financieros or its subsidiary, IEAF Servicios de Análisis S.L.U. held a long position of over 0.5% of the issuer's capital.
- 7. At the date of publication, the Instituto Español de Analistas Financieros or its subsidiary, IEAF Servicios de Análisis S.L.U. held a short position of over 0.5% of the issuer's capital.
- 8. At the end of the month immediately prior to the publication of this report, or of the previous month if the report is published in the ten days following the end of the month, the company analysed (the issuer) or any of its subsidiaries held 5% or more of any class of equity security of the Instituto Español de Analistas Financieros or its subsidiary, IEAF Servicios de Análisis S.L.U.
- 9. A senior director or officer of the Instituto Español de Analistas Financieros or its subsidiary, IEAF Servicios de Análisis S.L.U., or a member of their department is a director, officer, advisor or member of the Board of Directors of the issuer and/or one of its subsidiaries.
- 10. The Instituto Español de Analistas Financieros or its subsidiary, IEAF Servicios de Análisis S.L.U., acts as broker for the Issuer for the corresponding prepaid fees.
- 11. The contents of this report related to the financial analysis, financial projections, valuation, investment summary and opinion of the analyst have been reviewed by the issuer prior to its publication.
- 12. The issuer has made changes to the contents of this report prior to its distribution.

The Investment Analysts who have prepared this Investment Analysis are employees of IEAF Servicios de Análisis S.L.U. These analysts have received (or will receive) compensation according to the general earnings of IEAF Servicios de Análisis S.L.U. To obtain a copy of the Code of Conduct of IEAF Servicios de Análisis S.L.U. (in respect of the Management of Conflicts of Interest in the research department), please use the e-mail address secretaria@ieaf.es or consult the contents of this Code at www.ieaf.es.

IEAF Servicios de Análisis S.L.U. is compensated by Bolsas y Mercados Españoles, S.A. for the preparation of this report. This report should be considered as just another element in the taking of investment decisions.

### A report issued by IEAF servicios de análisis S.L.U.

All rights reserved. The unauthorised use or distribution of this report is prohibited. This document has been prepared and distributed, according to the provisions of the MiFID II by IEAF Servicios de Análisis S.L.U. Its corporate activity is regulated by the CNMV (the Spanish Securities Exchange Commission). The information and opinions expressed in this document do not represent nor are they intended to represent an offer or a solicitation to buy or sell the securities (in other words, the securities mentioned in this report and related warrants, options, rights or interests). The information and opinions contained in this document are based upon information available to the public and have been obtained from sources believed to be reliable by IEAF Servicios de Análisis S.L.U., but no guarantee is given regarding their accuracy or completeness. All comments and estimates reflect solely the opinion of IEAF Servicios de Análisis S.L.U. and do not offer any implicit or explicit guarantee. All the opinions expressed are subject to change without prior warning. This document does not take into account the specific investment objectives, financial position, risk profile or other specific aspects of the person who receives this document, and accordingly they should exercise their own judgement in this respect. Neither the Instituto Español de Análistas Financieros nor its subsidiary, IEAF Servicios de Análisis S.L.U., assumes any responsibility for direct or indirect losses arising from the use of the published research, except in the event of negligent conduct by IEAF Servicios de Análisis S.L.U. The information contained in this report is approved for distribution to professional clients, eligible counterparties and professional advisers, but not for distribution to private individuals or retail clients. Its reproduction, distribution or





(NTH-ES / NTH SM) Report date: 2 Mar 2022

publication for any purpose without the written authorisation of IEAF Servicios de Análisis S.L.U. is prohibited. The Instituto Español de Analistas Financieros (IEAF) and/or its subsidiary IEAF Servicios de Análisis S.L.U., their employees and directors, may hold a position (long or short) in an investment knowing that this issuer will be the object of analysis and that this analysis will be distributed to institutional investors. Any further information regarding the contents of this report will be provided upon request. IEAF Servicios de Análisis S.L.U. intends to publish (at least) one quarterly report or note updating the information on the company analysed.

United States. IEAF Servicios de Análisis S.L.U. is not registered in the United States and, consequently, is not subject to the regulations of that country governing the preparation of research and the independence of analysts. This report is distributed solely to major US institutional investors, in reliance on the exemption from registration provided by Rule 15a-6 of the US Securities Exchange Act of 1934, as amended (the "Exchange Act"), and interpretations of this made by the US Securities Exchange Commission.

Major US Institutional Investors. This report will be distributed to "major US institutional investors", as defined by Rule 15a-6 of the US Securities Exchange Commission and of the US Securities Exchange Act of 1934.

### **Notes and Reports History**

| Date of report | Recommendation | Price<br>(EUR) | Target price<br>(EUR) | Period of<br>validity | Reason for report                   | Analyst                          |
|----------------|----------------|----------------|-----------------------|-----------------------|-------------------------------------|----------------------------------|
| 02-Mar-2022    | n.a.           | 1.88           | n.a.                  | n.a.                  | 12m Results 2021                    | Luis Esteban Arribas             |
| 21-Sep-2021    | n.a.           | 1.71           | n.a.                  | n.a.                  | 6m Results 2021                     | Alfredo Echevarría Otegui        |
| 22-Jun-2021    | n.a.           | 1.69           | n.a.                  | n.a.                  | 3m Results 2021 - Estimates upgrade | Ana Isabel González García, CIIA |
| 23-Apr-2021    | n.a.           | 1.63           | n.a.                  | n.a.                  | Initiation of Coverage              | Ana Isabel González García, CIIA |

